- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 31/5375 - 1,4-Oxazines, p. ex. morpholine
Détention brevets de la classe A61K 31/5375
Brevets de cette classe: 1616
Historique des publications depuis 10 ans
|
101
|
102
|
104
|
103
|
98
|
90
|
81
|
96
|
98
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 136 |
25 |
| Apnimed, Inc. (Delaware) | 53 |
22 |
| Axsome Therapeutics, Inc. | 287 |
21 |
| Bristol-myers Squibb Company | 4783 |
18 |
| Novartis AG | 10505 |
15 |
| Allergan, Inc. | 2303 |
15 |
| Aeromics, Inc. | 29 |
13 |
| The Regents of the University of California | 20327 |
11 |
| Arbor Pharmaceuticals, LLC | 67 |
11 |
| Epizyme, Inc. | 369 |
11 |
| Gilead Sciences, Inc. | 2117 |
11 |
| Boehringer Ingelheim International GmbH | 4596 |
10 |
| Centre National de La Recherche Scientifique | 10760 |
10 |
| Mitsubishi Tanabe Pharma Corporation | 548 |
10 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2922 |
10 |
| Advanced Biodesign | 21 |
9 |
| Astellas Pharma Inc. | 1049 |
9 |
| The Cleveland Clinic Foundation | 1582 |
9 |
| Global Blood Therapeutics, Inc. | 182 |
9 |
| XenoPort, Inc. | 81 |
9 |
| Autres propriétaires | 1358 |